Navigation Links
TGen Drug Development partners with Horizon Discovery for integrated personalized medicine service
Date:4/12/2010

SCOTTSDALE, Ariz., and Cambridge, U.K. April 12, 2010 A strategic alliance announced today between TGen Drug Development (TD2) and Horizon Discovery Limited will significant advance personalized medicine.

The partnership will create a beginning-to-end solution for pharmaceutical and biotechnology companies to more rationally design and tailor their drugs to specific patient populations based on the unique genetic variations that define a given disease.

TD2 will use Horizon's panel of more than 200 genetically-defined human isogenic cell-lines designed to accurately mirror cancer patient genetics in its comprehensive pre-clinical service as a prelude to performing selected in-house clinical trials. This will provide clients with a fully integrated drug discovery service that will accelerate the isolation and optimization of appropriately targeted therapeutic agents and attain their rapid market approval. And it will save time and money in the development of more effective cancer treatments.

"The future of oncology drug development will require us to predict which patients will respond to what drug," said Dr. Stephen Gately, TD2's President and Chief Scientific Officer, referring to the goal of personalized medicine treating patients with drugs tailor-made for their specific diseases.

"This partnership is the engine that will actually make this work and allow for the design of shorter and less-costly clinical trials that enroll the patients most likely to respond to a given drug," Gately said.

Today's agreement between TD2 and Horizon builds on another agreement announced Feb. 2 between Horizon and TD2's parent organization, the Translational Genomics Research Institute (TGen), to develop new human disease models for TGen's cancer research.

"Working with TD2 will enable us to broaden the impact of our GENESIS and X-MAN technologies in the quest for therapies that target the genetic causes of cancer in each patient's tumor," said Dr. Chris Torrance, CEO of Horizon, based in Cambridge, U.K.

Horizon's new GENESIS technology allow researchers, for the first time, to routinely and precisely alter any specific gene or genomic location in a human cell. This would allow, for example, the ability to take a non-cancerous cell and mutate it to create a cancerous cell that matches the mutation in a given patient's tumor. Researchers then can test potential treatments on the cell pairs to define which specific mutation status confers the maximal drug activity. These engineered lines and their matched controls can be rapidly deployed in target validation, drug screening, patient profiling, drug resistance and drug re-profiling.

TD2 also has the expertise and capabilities to perform de novo high-throughput synthetic lethal screens that targets the nearly 3-billion-letter human genome, the DNA blueprint that makes us who we are. This will enable users to define the next generation of patient-relevant drug targets. Along with TD2's world-class preclinical, clinical and regulatory affairs expertise, it will ensure that client's targets and drugs will move quickly from the laboratory bench to the patient bedside.

TD2 will provide high-throughput screening capabilities, study execution and business marketing, and may incorporate new service offerings that emerge from its affiliated organizations, TGen and the Van Andel Research Institute.

Horizon through its subsidiary Horizon Discovery Services will support the pre-clinical offerings with bespoke 2D and 3D assay formats that closely mimic the in vivo phenotype being driven by primary and secondary genetic cancer mutations. A key part of identifying the correct phenotype is the ability to replicate the context of the mutation in the actual tumour microenvironment.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Poverty Can Slow Kids Normal Development
2. SCDM to Showcase Professional Development Opportunities at Partnerships Event
3. Urine test for kidney cancer a step closer to development
4. Exposure to 3 classes of common chemicals may affect female development
5. RapidValue Launches iPad Application Development Services for Media & Publishing Firms
6. McMaster researcher leads development of promising drug for inflammation
7. Rapid development of drug-resistant 2009 H1N1 influenza reported in 2 cases
8. Researchers discover fundamental step in immune-system development
9. EP Global Communications, Inc. Closes First Quarter With Positive Developments
10. Global Development Successes Depend on Access to Water
11. Gene is linked to lung cancer development in never-smokers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... NJ (PRWEB) , ... May 26, 2017 , ... Water ... Fort Lee, New Jersey School District had left education officials with a number of ... and replacement of the flooring had to be accomplished with little or no disruption ...
(Date:5/24/2017)... CA (PRWEB) , ... May 24, 2017 , ... ... today its participation in nVerge 2017 – a one-day technology conference in San Diego, ... document management solution, which allows users to fully utilize and enhance their Sage ERP ...
(Date:5/24/2017)... ... May 24, 2017 , ... Patients who want to receive ... now meet with Dr. Joseph Bedich for a consultation, with or without a referral. ... oral health and functionality. , Dr. Bedich offers a variety of cosmetic ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... in which the endometrial lining of the uterus spreads into the pelvic ... experiencing painful intercourse, painful periods, pelvic pain, or irregular bleeding may have ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... is offering holistic pediatric dentistry options for its patients on Long Island, New ... patient’s entire physical well being, and is one of the biggest trends in ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... WHIPPANY, N.J. , May 17, 2017  Bayer ... growing oncology portfolio will be presented at the 53 ... Clinical Oncology (ASCO), taking place June 2-6 in ... being presented at ASCO span prostate, colorectal, liver and ... subgroup analysis from the Phase II CHRONOS-1 trial of ...
(Date:5/11/2017)... , May 11, 2017  Thornhill Research Inc. ... been awarded an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery ... the Canadian Commercial Corporation (CCC) ( Ottawa, ... Systems to administer general anesthesia to patients requiring ... "The US Marine Corps have been a ...
(Date:5/10/2017)... 10, 2017 Radiology has become the number ... have also spiraled to the number one ranking as ... than ever before as the most complete and reliable ... with lower back pain an MRI may confirm a ... pain, resulting in entirely different treatment protocols.  In these ...
Breaking Medicine Technology: